109 related articles for article (PubMed ID: 3181395)
1. Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia.
Mortensen BT; Ernst P; Philip P
Eur J Haematol; 1988 Sep; 41(3):218-22. PubMed ID: 3181395
[TBL] [Abstract][Full Text] [Related]
2. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
[TBL] [Abstract][Full Text] [Related]
3. Mafosfamide induces less sister chromatid exchange in Ph-positive cells than in normal bone marrow.
Becher R; Becker G; Schmidt CG
Haematol Blood Transfus; 1990; 33():133-6. PubMed ID: 2323626
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
5. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Rizzoli V; Mangoni L
Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
[TBL] [Abstract][Full Text] [Related]
7. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
[TBL] [Abstract][Full Text] [Related]
9. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
[TBL] [Abstract][Full Text] [Related]
10. Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging.
Rizzoli V; Mangoni L; Piovani G; Garau D; Caramatti C; Almici C; Carlo-Stella C
Leuk Lymphoma; 1993; 11 Suppl 1():109-12. PubMed ID: 8251884
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
12. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
13. Long-term culture of chronic myeloid leukemia (CML) bone marrow cells.
Santucci MA; Zaccaria A; Testoni N; Russo D; Zuffa E; Baccarani M; Tura S
Haematologica; 1991; 76(5):357-62. PubMed ID: 1806437
[TBL] [Abstract][Full Text] [Related]
14. [Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development].
Fouillard L; Van Den Akker J; Laporte JP; Najman A; Perot C; Lopez M; Douay L; Isnard F; Taillemite JL; Gorin NC
Presse Med; 1989 Nov; 18(36):1785-8. PubMed ID: 2530566
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
Geissler D; Gastl G; Aulitzky W; Tilg H; Gaggl S; Konwalinka G; Huber C
Leuk Res; 1990; 14(7):629-36. PubMed ID: 2388474
[TBL] [Abstract][Full Text] [Related]
16. Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
Rizzoli V; Mangoni L; Almici C; Caramatti C; Dotti GP; Carlo-Stella C
Stem Cells; 1993 Oct; 11 Suppl 3():25-30. PubMed ID: 8298474
[TBL] [Abstract][Full Text] [Related]
17. Difference of cell lineage expression of haematopoietic progenitor cells in Philadelphia-positive acute lymphoblastic leukaemia and chronic myelogenous leukaemia.
Kitano K; Sato Y; Suda T; Miura Y
Br J Haematol; 1988 Sep; 70(1):21-6. PubMed ID: 3179225
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
Douay L; Mary JY; Giarratana MC; Najman A; Gorin NC
Exp Hematol; 1989 Jun; 17(5):429-32. PubMed ID: 2653856
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic studies of early myeloid progenitor compartments in Ph1-positive chronic myeloid leukemia. II. Long-term culture reveals the persistence of Ph1-negative progenitors in treated as well as newly diagnosed patients.
Dubé ID; Kalousek DK; Coulombel L; Gupta CM; Eaves CJ; Eaves AC
Blood; 1984 May; 63(5):1172-7. PubMed ID: 6585234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]